Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Epileptic encephalopathy

Recruiting

Study of intrathecal S230815 to evaluate safety and effectiveness in children with KCNT1-related Developmental and Epileptic Encephalopathy

InvestigationalNo placebo

Study of intrathecal S230815 to evaluate safety and effectiveness in children with KCNT1-related Developmental and Epileptic Encephalopathy

InvestigationalNo placebo

France

Participants:0–17 years
Substances:S230815-2
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of etentamig and iberdomide treatment for patients with relapsed or refractory multiple myeloma

InvestigationalNo placebo

Study of etentamig and iberdomide treatment for patients with relapsed or refractory multiple myeloma

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Iberdomide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Chronic graft versus host disease

Recruiting

Study of belumosudil in children aged 1 to 18 years with moderate to severe chronic graft versus host disease requiring systemic treatment

InvestigationalNo placebo

Study of belumosudil in children aged 1 to 18 years with moderate to severe chronic graft versus host disease requiring systemic treatment

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Belumosudil Mesilate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Brain neoplasm

Recruiting

Study of Tarlatamab and Temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

Study of Tarlatamab and Temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:Centre Leon Berard

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ambrisentan
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Adenocarcinoma pancreas+2

Recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Novartis Pharma AG

Contact Research Centre

Cryoglobulinaemia

Recruiting

Study of Obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate Rituximab

Registered drugNo placebo

Study of Obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate Rituximab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Marseille

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for head and neck squamous cell carcinoma, examining novel therapies and combinations with radiotherapy. Research includes investigations into endometrial cancer and bladder cancer treatments.

Advanced tumor treatments
Immunotherapy combinations
Targeted therapies

Particular emphasis on combining immunotherapy with conventional treatments for improved patient outcomes.

02 Cardiovascular and Metabolic Disorders

Innovative research addressing heart failure prevention and treatment of acute myocardial infarction. Studies include new approaches for managing hypertriglyceridemia and chronic kidney disease.

Preventive cardiology
Emergency cardiac care
Metabolic conditions

Focus on developing novel therapeutic approaches and improving patient outcomes in cardiovascular health.

03 Neurological Conditions

Clinical investigations into multiple sclerosis treatment strategies and management of essential tremor. Research includes innovative approaches for Dravet Syndrome and neurological disorders.

Movement disorders
Autoimmune conditions
Seizure management

Emphasis on developing targeted therapies for various neurological conditions affecting both adults and children.

Back to France All countries